ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies – Pharmaceutical Processing
Pharmaceutical ProcessingViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell ImmunotherapiesPharmaceutical ProcessingViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, this week a… Continue reading
